SYHA 1807
Alternative Names: SYHA-1807Latest Information Update: 25 Apr 2023
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class Antineoplastics; Small molecules
- Mechanism of Action Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Small cell lung cancer
Most Recent Events
- 25 Apr 2023 SYHA 1807 is still in phase I trials for Small cell lung cancer in China (CSPC Pharmaceutical Group pipeline, April 2023).
- 28 Dec 2022 No recent reports of development identified for phase-I development in Small-cell-lung-cancer in China
- 27 May 2020 CSPC ZhongQi Pharmaceutical Technology plans a phase I trial for Small-cell lung cancer (Late-stage disease) (NCT04404543)